{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:08:26Z","timestamp":1785449306991,"version":"3.56.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.waojou.2023.100741","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:40:13Z","timestamp":1673239213000},"page":"100741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Omalizumab may protect allergic patients against COVID-19: A systematic review"],"prefix":"10.1016","volume":"16","author":[{"given":"Daniele Giovanni","family":"Ghiglioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Castagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Bruschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Giovanna","family":"Marchisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luigi","family":"Marseglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Licari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib1","first-page":"153","article-title":"Asthma and COVID-19 associations: focus on IgE-related immune pathology","volume":"12","author":"Wang","year":"2022","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/08923973.2021.1925906","article-title":"Anti-IgE monoclonal antibodies as potential treatment in COVID-19","volume":"43","author":"Farmani","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100741_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/biomedicines9040348","article-title":"Immunological aspects related to viral infections in severe asthma and the role of omalizumab","volume":"9","author":"Menzella","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.waojou.2023.100741_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir Res"},{"issue":"62","key":"10.1016\/j.waojou.2023.100741_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"issue":"9","key":"10.1016\/j.waojou.2023.100741_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"issue":"6515","key":"10.1016\/j.waojou.2023.100741_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08923973.2020.1818770","article-title":"Future perspective: biologic agents in patients with severe COVID-19","volume":"43","author":"Yalcin","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144455","article-title":"An immune-based biomarker signature is associated with mortality in COVID-19 patients","volume":"6","author":"Abers","year":"2021","journal-title":"JCI insight"},{"issue":"11","key":"10.1016\/j.waojou.2023.100741_bib10","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1111\/all.14407","article-title":"Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement","volume":"75","author":"Vultaggio","year":"2020","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-\u03b1 subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.waojou.2023.100741_bib12","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.3390\/ijms22084190","article-title":"Type I interferon production of plasmacytoid dendritic cells under control","volume":"22","author":"Bencze","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib14","doi-asserted-by":"crossref","first-page":"L880","DOI":"10.1152\/ajplung.00547.2020","article-title":"Implications of preexisting asthma on COVID-19 pathogenesis","volume":"320","author":"Ramakrishnan","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-020-08797-3","article-title":"COVID-19 and asthma: reflection during the pandemic","volume":"59","author":"Liu","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/all.14426","article-title":"Is asthma protective against COVID-19","volume":"76","author":"Carli","year":"2021","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.waojou.2023.100741_bib17","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1111\/all.14456","article-title":"COVID-19 in a patient with severe asthma treated with Omalizumab","volume":"75","author":"Lommatzsch","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib18","first-page":"68","article-title":"Mild COVID-19 respiratory infection associated with moderate fare of chronic spontaneous urticaria in a 43-year old female long-term care worker on omalizumab","volume":"17","author":"Lanoue","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"10.1016\/j.waojou.2023.100741_bib19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/ijd.15134","article-title":"Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab","volume":"59","author":"Criado","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.waojou.2023.100741_bib20","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/all.15004","article-title":"A\u00a0bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: perspectives for immune-based vaccines","volume":"77","author":"Galati","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.jaci.2021.03.011","article-title":"Asthma and viruses: a focus on rhinoviruses and SARS-CoV-2","volume":"147","author":"Padayachee","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jaip.2020.12.067","article-title":"One hundred ten years of allergen immunotherapy: a broad look into the future","volume":"9","author":"Pfaar","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5644\/ama2006-124.292","article-title":"Respiratory virus infections in asthma: research developments and therapeutic advances","volume":"49","author":"Kumar","year":"2020","journal-title":"Acta Med Acad"},{"key":"10.1016\/j.waojou.2023.100741_bib25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaci.2012.05.023","article-title":"Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children","volume":"130","author":"Durrani","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100741_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14068","article-title":"What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?","volume":"33","author":"Criado","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","article-title":"Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab","volume":"141","author":"Gill","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.waojou.2023.100741_bib29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2019.01.016","article-title":"New insights into the utility of omalizumab","volume":"143","author":"Cardet","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100741_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1179548420966242","article-title":"Asthma and COVID-19: what do we know now","volume":"14","author":"Hughes-Visentin","year":"2020","journal-title":"Clin Med Insights Circulatory, Respir Pulm Med"},{"issue":"7","key":"10.1016\/j.waojou.2023.100741_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12065","article-title":"Recent advances and developments in COVID-19 in the context of allergic diseases","volume":"11","author":"Ding","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5578\/tt.69775","article-title":"Asthma and COVID-19: what do we know?","volume":"68","author":"Sar\u0131o\u011flu","year":"2020","journal-title":"Tuberk Toraks"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40733-021-00075-z","article-title":"Asthma and COVID-19: a dangerous liaison?","volume":"7","author":"Lombardi","year":"2021","journal-title":"Asthma Res Pract"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib35","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/all.14453","article-title":"COVID-19 pandemic: practical considerations on the organization of an allergy clinic-An EAACI\/ARIA Position Paper","volume":"76","author":"Pfaar","year":"2021","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib36","first-page":"1477","article-title":"COVID-19: pandemic contingency planning for the allergy and immunology clinic","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5114\/pja.2020.99242","article-title":"Position statement of expert panel of the Polish Allergology Society on the management of patients with bronchial asthma and allergic diseases during SARS-Cov-2 pandemics","volume":"7","author":"Kowalski","year":"2020","journal-title":"Alergologia Polska \u2013 Polish Journal of Allergology"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100741_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1203475420929250","article-title":"Preliminary data suggests that biologics in dermatology are not associated with adverse COVID-19 outcomes","volume":"24","author":"Nassim","year":"2020","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.waojou.2023.100741_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02857-2020","article-title":"COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry","volume":"56","author":"Hanon","year":"2020","journal-title":"Eur Respir J"},{"issue":"162","key":"10.1016\/j.waojou.2023.100741_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0152-2021","article-title":"Asthma and COVID-19: an update","volume":"30","author":"Adir","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/all.14558","article-title":"Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: results from the Italian Severe Asthma Registry","volume":"76","author":"Antonicelli","year":"2021","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03142-2020","article-title":"The impact of COVID-19 on patients with asthma","volume":"57","author":"Izquierdo","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/all.14516","article-title":"COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: results from a multicenter Italian survey","volume":"76","author":"Matucci","year":"2021","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.waojou.2023.100741_bib45","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.jaip.2020.06.027","article-title":"Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy","volume":"8","author":"Dom\u00ednguez-Ortega","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaip.2020.09.050","article-title":"Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak","volume":"9","author":"Rial","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/all.14480","article-title":"COVID-19 and asthma, the good or the bad?","volume":"76","author":"Wang","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2023.100741_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.570721","article-title":"Outcomes and laboratory and clinical findings of asthma and allergic patients admitted with covid-19 in a Spanish university hospital","volume":"11","author":"Garc\u00eda-Menaya","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.waojou.2023.100741_bib49","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/14712598.2020.1807933","article-title":"Immunotherapy for SARS-CoV-2: potential opportunities","volume":"20","author":"Pashaei","year":"2020","journal-title":"Expet Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.waojou.2023.100741_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ijd.15215","article-title":"Comment on \"Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab","volume":"59","author":"Abdelmaksoud","year":"2020","journal-title":"Int J Dermatol"},{"issue":"11-S","key":"10.1016\/j.waojou.2023.100741_bib51","article-title":"SARS-CoV-2 infection in pediatric population","volume":"91","author":"Manti","year":"2020","journal-title":"Acta Biomed"},{"issue":"7902","key":"10.1016\/j.waojou.2023.100741_bib52","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.waojou.2023.100741_bib53","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/v13091839","article-title":"Type I interferon induction and exhaustion during viral infection: plasmacytoid dendritic cells and emerging COVID-19 findings","volume":"13","author":"Greene","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.waojou.2023.100741_bib54","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamapediatrics.2020.1467","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review","volume":"174","author":"Castagnoli","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"12","key":"10.1016\/j.waojou.2023.100741_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100614","article-title":"Pediatric usage of Omalizumab: a promising one","volume":"14","author":"Yu","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.waojou.2023.100741_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/ped.2020.1214","article-title":"Biologic use in allergic and asthmatic children and adolescents during the COVID-19 pandemic","volume":"33","author":"Licari","year":"2020","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"8","key":"10.1016\/j.waojou.2023.100741_bib57","first-page":"795","article-title":"COVID-19 and immunological regulations - from basic and translational aspects to clinical implications","volume":"18","author":"Sch\u00f6n","year":"2020","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.waojou.2023.100741_bib58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.anai.2020.06.001","article-title":"Children and adolescents with allergy and\/or asthma seem to be protected from coronavirus disease 2019","volume":"125","author":"Ciprandi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"S7","key":"10.1016\/j.waojou.2023.100741_bib59","article-title":"Allergy and COVID-19","volume":"92","author":"De Filippo","year":"2021","journal-title":"Acta Biomed"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imm.13240","article-title":"Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2","volume":"161","author":"Novak","year":"2020","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaci.2020.04.009","article-title":"Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2","volume":"146","author":"Jackson","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100741_bib62","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1128\/JVI.00527-07","article-title":"Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome","volume":"81","author":"Cameron","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.waojou.2023.100741_bib63","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100741_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100741_bib65","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/all.14316","article-title":"Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2023.100741_bib66","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaci.2020.06.010","article-title":"Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19","volume":"146","author":"Chhiba","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100741_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100126","article-title":"COVID-19, asthma, and biological therapies: what we need to know","volume":"13","author":"Morais-Almeida","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2023.100741_bib69","article-title":"Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy","volume":"177","author":"Eger","year":"2020","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.waojou.2023.100741_bib70","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40272-014-0107-z","article-title":"Omalizumab in children","volume":"16","author":"Licari","year":"2014","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.waojou.2023.100741_bib71","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/cea.14023","article-title":"Hypersensitivity may be involved in severe COVID-19","volume":"52","author":"Tan","year":"2022","journal-title":"Clin Exp Allergy"}],"updated-by":[{"DOI":"10.1016\/j.waojou.2025.101059","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:30Z","timestamp":1761849990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1939455123000017"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100741","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab may protect allergic patients against COVID-19: A systematic review","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100741"}}